Biote corp.

May 31, 2022 · Biote Corp. biote Corp. provides precision and preventive medicines. The Company offers hormone therapy and products that boosts energy and immune system. biote serves customers worldwide.

Biote corp. Things To Know About Biote corp.

Biote Corp. Consolidated Balance Sheets (In Thousands) (Unaudited) September 30, December 31, 2023 2022 Assets: Current assets: Cash and cash equivalents $ 65,575 $ 79,231 Short ...Full Year 2022 Highlights, year over year: Revenue of $165.0 million, an 18.3% increase. Net income of $1.3 million and fully diluted GAAP loss per share of $ (0.12) . “Biote achieved record financial results in the fourth quarter and for the full 2022 year, driven by strong growth in revenue and Adjusted EBITDA, which were at the high end of ...Biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote-certified practitioners to establish, build, and implement a program designed to optimize hormone levels. The Company's Biote Method is a comprehensive, end-to-end practice …Biote Corp. Warrant Tender Offer. Financial Advisor June 2023. $49,680,000. GEN Restaurant Inc. IPO. Sole Book-Running Manager June 2023 View Details.

May 9, 2023 · Biote Corp. Consolidated Statements of Operations (In Thousands, except per share values) (Unaudited) Three Months Ended March 31, 2023. 2022. Revenue: Product revenue $ 44,155 $ 36,758. Service ...

On May 26, 2022, Haymaker completed the Business Combination with Biote and changed its name to “biote Corp.”. On May 26, 2022, the Company issued a press release announcing the consummation of the Business Combination. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Exhibit 99.1 . Biote Appoints Debby Morris to Board of Directors . IRVING, TX – November 7, 2022 – biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading innovator in preventive health care through the delivery of personalized hormone therapy, today announced the appointment of Debby Morris to Biote’s Board of Directors.biote Corp. Up to 72,069,990 Shares of Class A Common Stock . Up to 67,856,462 Shares of Class A Common Stock . Up to 5,566,666 Warrants. This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-265714), as amended. Terry joined Biote to drive permanent industry innovation in the hormone optimization market, addressing the 200 million individuals in the U.S. who suffer from hormone imbalance. Terry’s team-first focus has consistently resulted in growth, both in the financials of the $100 million to $2.5 billion companies she has led, and in the personal ...Nov 7, 2023 · Item 2.02. Results of Operations and Financial Condition. On November 7, 2023, biote Corp., a Delaware corporation (the “Company”) issued a press release to report the Company’s financial results for the quarter ended September 30, 2023. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Biote Appoints Samar Kamdar as Chief Financial Officer IRVING, TX, August 24, 2022 — biote Corp. (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today announced that it has appointed Samar Kamdar as its Chief Financial Officer.

Haymaker management is a uniquely qualified team boasting C-suite operational experience at Fortune 500 companies and deep knowledge in both public and private equity investing. Haymaker executives have experience in public and private equity as well as operations and strategy, making them an ideal manager and sponsor for a new public company.

Third Quarter 2023 Financial Highlights. (All financial result comparisons made are against the prior year period) Revenue of $45.6 million, an 8.5% increase. Gross profit margin of 68.9%, a 70-basis point increase. Net income of $19.6 million, representing net income margin of 43.1%, and basic earnings per share of $0.25, compared to net ...Item 4.02. Non-Reliance on Previously Issued Financial Statements or a Related. Audit Report or Completed Interim Review. (a) On March 24, 2023, the audit committee of the board of directors (the "Audit Committee") of biote Corp. (the "Company"), based on the recommendation of, and after consultation with, the Company's …In this case, outsourcing facilities, Carie Boyd’s Prescription Shop and AnazaoHealth Corporation, produced the pellets, but they were marketed by BioTe Medical, which was not registered with ...Oct 24, 2023 ... IRVING, Texas--(BUSINESS WIRE)-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of hormone optimization, today ...IRVING, Texas, October 24, 2023--biote Corp. (Nasdaq: BTMD) ("Biote" or the "Company"), a leading provider of hormone optimization, today announced the Company …

Innovative physician leader brings over 20 years of experience to Biote’s executive team. IRVING, Texas--(BUSINESS WIRE)--Jun. 16, 2022-- biote Corp. (“Biote” or the “Company”) (Nasdaq: BTMD), a high growth, medical practice-building business within the hormone optimization space, today announced that it has appointed Ross W. …On March 4, 2021, HYAC completed its IPO. On the Closing Date, the Business Combination with Biote was consummated, resulting in the Combined Company being organized in an “Up-C” structure, and HYAC as the registrant changed its name to “biote Corp.” Biote’s headquarters is located at 1875 W. Walnut Hill Ln #100 Irving, Texas 75038.A certain stockholder of biote Corp., a Delaware corporation (the “Company”) named in Schedule II attached hereto (the “Selling Stockholder”), propose, subject to the terms and conditions herein, to sell 5,217,392 shares (the “Firm Shares”) of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”).Biote is the nation's largest hormone optimization company and one of the only companies actively contributing to furthering the science behind hormone ...BIGBEAR AI HOLDINGS CORP. BBAI. Technology. BIOATLA. BCAB. Health Care. BIOMEA FUSION. BMEA. Health Care. BIOTE CORP. BTMD. Health Care. BIOVIE. BIVI. Health ...

BioTE's Pellet Therapy uses BioTE's custom and proprietary hormone pellet for ... Iowa Marine and Repair Corp., 16 F.3d 82, 85 (5th Cir.1994). As Defendants ...

The Investor Relations website contains information about biote Corp's business for stockholders, potential investors, and financial analysts.Nov 7, 2022 · IRVING, Texas -- (BUSINESS WIRE)--Nov. 7, 2022-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading innovator in preventive health care through the delivery of personalized hormone therapy, today announced the appointment of Debby Morris to Biote’s Board of Directors. Ms. Morris brings more than three decades of ... biote Corp. 1875 W. Walnut Hill Ln #100 Irving, TX 75038 (312) 212-8079 (Name, address, including zip code, and telephone number, including area code, of agent for service) Copies to: Ryan Sansom Peter Byrne Cooley LLP 500 Boylston Street Boston, MA 02116-3736 (617) 937-2300 Steven Burwell Proskauer Rose LLP 11 Times Square New York, NY …America’s largest Marine Corps bases include North Carolina’s Marine Corps Base Camp Lejeune, and California’s Marine Corps Air Ground Combat Center Twentynine Palms and Marine Corps Base Camp Pendleton.biote Corp. has announced the launch of a new Men's Health Division with the mission of redefining wellness for men through innovation in hormone education and optimization. Coinciding with National Men's Health Month and headed by Biote General Manager John Denne, this new division will focus on increasing awareness, education …TO BE HELD ON MAY 24, 2022. On May 5, 2022, Haymaker Acquisition Corp. III (“Haymaker” or the “Company”) filed a Definitive Proxy Statement on Schedule 14A (the “Proxy Statement”) with the Securities and Exchange Commission (“SEC”) in connection with the Business Combination Agreement, dated as of December 13, 2021 (as amended ...Biote Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023 May. 09: CI Certain Restricted Stock Units of biote Corp. are subject to a Lock-Up Agreement Ending on 6-APR-2023. Apr. 05: CI Certain Stock Options of biote Corp. are subject to a Lock-Up Agreement Ending on 6-APR-2023.

Haymaker Acquisition Corp 4. Haymaker Acquisition Corp. 4 operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange ...

On May 26, 2022, Haymaker completed the Business Combination with Biote and changed its name to “biote Corp.”. On May 26, 2022, the Company issued a press release announcing the consummation of the Business Combination. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

IRVING, Texas, March 28, 2023 -- ( BUSINESS WIRE )-- Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today ...Nov 7, 2022 · IRVING, Texas -- (BUSINESS WIRE)--Nov. 7, 2022-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading innovator in preventive health care through the delivery of personalized hormone therapy, today announced the appointment of Debby Morris to Biote’s Board of Directors. Ms. Morris brings more than three decades of ... Mar 28, 2023 · IRVING, Texas, March 28, 2023--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced financial results ... Aug 10, 2023 · Biote Corp. (BTMD) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.27 per share a year ago. Dec 12, 2021 · Biote Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023 May. 09: CI Certain Restricted Stock Units of biote Corp. are subject to a Lock-Up Agreement Ending on 6-APR-2023. Apr. 05: CI Certain Stock Options of biote Corp. are subject to a Lock-Up Agreement Ending on 6-APR-2023. A certain stockholder of biote Corp., a Delaware corporation (the “Company”) named in Schedule II attached hereto (the “Selling Stockholder”), propose, subject to the terms and conditions herein, to sell 5,217,392 shares (the “Firm Shares”) of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”).Conference Call: Biote management will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET on Wednesday, November 8, 2023. To access the conference call by telephone, please dial (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). To access a live webcast of the call, interested ...Biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote …biote Corp. Up to 72,069,990 Shares of Class A Common Stock . Up to 67,856,462 Shares of Class A Common Stock . Up to 5,566,666 Warrants. This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-265714), as amended.Lead author Dr. Bruce Dorr, an educational consultant for Biote, provided counseling to the patient and then initiated testosterone pellet therapy together with 10,000 IU/day of a vitamin d3k2 nutraceutical formulation and DIM (diindoyl methane) 300 mg, “a nutraceutical grade formula known to prevent aromatization,” a process that turns …biote Corp stock performance at a glance. Check biote Corp’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value.

The Investor Relations website contains information about biote Corp's business for stockholders, potential investors, and financial analysts.Biote Corp. (BTMD) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of $0.08. This compares to loss of $0.09 per share a year ago. These figures are adjusted ...biote Corp. is a woman-led company, which engages in providing bio identical hormone pellet therapy. It delivers a comprehensive, end-to-end platform that provides practitioners with medical ... biote Corp. has completed a Follow-on Equity Offering in the amount of $27.913047 million. Jun 06. Biote Corp. Appoints Mary J. Puncochar as Chief Commercial Officer May 31. biote Corp. Provides Earnings Guidance for the Year 2023 May 10. biote Corp. to Report Q4, 2022 Results on Mar 28, 2023Instagram:https://instagram. oil to invest ingold mining stocksbest dental insurance tnnso nursing insurance reviews Achieved Full Year 2022 Record Revenue and Adjusted EBITDA for Full Year 2022 Expect 2023 Revenue of $190-200 million and Adjusted EBITDA of $56-60 million Significantly Increased Trading Liquidity with Recent Successful Secondary Offering IRVING, Texas --(BUSINESS WIRE)--Mar.Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years. Given the positive cash flows generated by its business, the company's valuation level is an asset. Analysts covering this company mostly recommend stock overweighting or purchase. adoestockchat gbt stock price Biote Method to be available in IMAC outpatient medical clinics . IRVING, Texas--(BUSINESS WIRE)--Sep. 7, 2022-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today announced that it has entered into a partnership with …The Investor Relations website contains information about biote Corp's business for stockholders, potential investors, and financial analysts. coinbase alternative us Our success will depend upon whether the Biote Method and our Biote-branded dietary supplements attain significant market acceptance among clinics, practitioners and their patients; Outsourcing facilities that produce bioidentical hormone pellets that we offer training on in the Biote Method and failure by those parties to adequately perform their …The Investor Relations website contains information about biote Corp's business for stockholders, potential investors, and financial analysts.